Stroke risk in atrial fibrillation: Do we anticoagulate CHADS2 or CHA2DS2-VASc ≥1, or higher?
Jonas Bjerring
JB
Olesen
Prof. Christian Torp-Pedersen, Department of Health, Science and Technology, Aalborg University, Niels Jernes Vej 12, 9220 Aalborg, Denmark, E-mail: ctp@hst.aau.dk.
Christian
C
Torp-Pedersen
D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D003661:Decision Support Techniques; D019317:Evidence-Based Medicine; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D018579:Patient Selection; D011237:Predictive Value of Tests; D018570:Risk Assessment; D012307:Risk Factors; D020521:Stroke / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D013997:Time Factors; D016896:Treatment Outcome
D000925:Anticoagulants